Metformin: Long COVID Risk Reduction and Diabetes Management
Imagine catching a virus that's tough enough on its own, but then it leaves a parting gift that changes your life: uncontrolled type II diabetes. That's what happened to me after COVID-19. Before that, I never had to think twice about my blood sugar levels. Now, it's like walking a tightrope without a safety net.
Every meal is a potential hazard, not because of calories or taste, but because of the sugar content that could send my blood glucose skyrocketing. I have to prick my fingers multiple times a day to check my blood sugar, and each little drop of blood is a reminder of this new reality.
The fatigue is overwhelming. It's not the kind of tiredness that a good night's sleep can fix. It's a deep, bone-weary exhaustion that makes it hard to do even the simplest tasks. And the thirst – it's insatiable. I drink water like I'm crossing a desert, but it never seems to be enough.
Then there's the worry about the long-term effects. I've read about the damage uncontrolled diabetes can do to the heart, the kidneys, the eyes, and it's like there's a ticking time bomb inside me that I'm desperately trying to defuse.
Metformin: A Multifaceted Medication for Diabetes, Long COVID Risk Reduction, Endothelial support, and More
Metformin is FDA-approved and is the first-line medication for controlling elevated blood sugar levels in people with type II diabetes. Beyond its primary role in diabetes care, metformin has also been found to have other potential health benefits including supporting weight loss, improving cardiovascular health, and potentially even contributing to longevity!
Not only that, but a randomized placebo-controlled study suggests that metformin may reduce a person’s chance of developing Long COVID by about 41% when it is taken during acute COVID-19 infection!
In addition to metformin’s ability to curb glucose uptake in the intestines, diminish glucose production in the liver, and enhance the body's responsiveness to insulin – it appears to have antiviral activity against SARS-CoV2 in a laboratory setting.
Metformin - derived from the French Lilac - has been used in healthcare for decades, has a great safety profile, and has very affordable generics available. All of this contributes to it being a great treatment on-label for type II diabetes but also off-label for things like Long COVID risk reduction, cardiovascular health, weight management, and even longevity support.
Metformin: The Potential Benefit for Acute COVID and Long COVID
Metformin's potential to reduce the risk of Long COVID is a promising area of research. While the exact mechanisms are not fully understood, several theories have been proposed based on its known pharmacological actions:
Anti-inflammatory Effects: Metformin has been shown to have anti-inflammatory properties. Since systemic inflammation is a hallmark of both acute COVID-19 and Long COVID, it is hypothesized that metformin's ability to reduce inflammation could potentially lessen the severity of the initial infection and decrease the likelihood of developing Long COVID.
Immunomodulatory Actions: Metformin may modulate the immune response, which could be beneficial in preventing the overactive immune reaction known as a cytokine storm, often associated with severe cases of COVID-19. By potentially mitigating this response, metformin could help prevent the long-term effects that result from it.
Endothelial Function Improvement: COVID-19 can cause endothelial dysfunction, which is linked to the blood clotting and vascular issues seen in Long COVID. Metformin is known to improve endothelial function, which might help in reducing these complications.
Metabolic Benefits: Given that metabolic health is a significant factor in COVID-19 outcomes, metformin's role in improving metabolic function could also contribute to a lower risk of developing Long COVID, particularly in individuals with pre-existing metabolic conditions like type 2 diabetes.
The Science Behind Metformin
Metformin's mechanisms of action are multifaceted and contribute to its effectiveness as a treatment for type 2 diabetes and its potential benefits for other conditions. Here are the primary mechanisms by which metformin operates:
Decreased Hepatic Glucose Production: Metformin primarily lowers blood glucose levels by inhibiting gluconeogenesis, which is the production of glucose by the liver. It decreases the liver's ability to produce glucose, especially when glucose levels are already elevated.
Increased Insulin Sensitivity: Metformin improves the sensitivity of peripheral tissues, such as muscle and adipose tissue, to insulin. This means that these tissues are better able to respond to insulin and take up glucose from the bloodstream, which helps lower blood sugar levels.
Decreased Intestinal Absorption of Glucose: Metformin can reduce the amount of glucose absorbed by the intestines from the diet, contributing to lower blood glucose levels post-meal.
GLUT4 Translocation: Metformin has been shown to increase the translocation of GLUT4 glucose transporters to the cell surface in muscle and fat cells, which enhances glucose uptake from the bloodstream.
AMP-activated Protein Kinase (AMPK) Activation: Metformin activates AMPK, an enzyme that plays a role in cellular energy homeostasis. The activation of AMPK results in a variety of actions, including the modulation of insulin signaling, energy metabolism, and the inhibition of the mTOR pathway, which can affect protein and lipid metabolism.
SARS-CoV2 Antiviral activity in vitro: Likely related to metformin’s effects on AMPK, it was found to reduce SARS-CoV2 viral replication by 99% in cultured cells infected with the virus
Gut Microbiota Modulation: Emerging research suggests that metformin may also exert effects by altering the composition and function of the gut microbiota, which could have implications for metabolic health and inflammation.
Anti-inflammatory and Cardiovascular Effects: Metformin has been observed to have anti-inflammatory effects, which may contribute to its cardiovascular benefits and potential impact on conditions characterized by systemic inflammation.
These mechanisms collectively contribute to the antihyperglycemic effects of metformin and may underlie its potential benefits in conditions beyond type 2 diabetes, such as polycystic ovary syndrome (PCOS), weight management, and possibly in reducing the severity or incidence of Long COVID. However, it's important to note that while metformin is well-studied for its use in diabetes, its effects on other conditions require further clinical research to fully understand and validate.
Safety and Efficacy
Metformin is widely recognized for its safety and efficacy, particularly in the treatment of type 2 diabetes. It has been used for decades and is often the first medication prescribed for managing high blood sugar levels in patients with type 2 diabetes due to its proven track record.
Metformin is generally well-tolerated by most patients. The most common side effects are gastrointestinal, including diarrhea, nausea, and abdominal discomfort, which can often be mitigated by taking metformin with food and by starting with a low dose and gradually increasing it. A rare but serious side effect is lactic acidosis, although this is more likely to occur in patients with kidney impairment or other contraindications.
In addition to its use in diabetes, metformin has been studied for potential benefits in other areas, such as cardiovascular disease prevention and treatment of polycystic ovary syndrome (PCOS). Its role in these conditions is supported by its metabolic, anti-inflammatory, and potential endothelial protective effects.
While the use of metformin in the context of COVID-19 and Long COVID is an area of ongoing research, it is not yet a standard part of treatment protocols for these conditions.
The Path Forward
As we continue to navigate the waters of COVID-19 and Long COVID, metformin has the potential to be a powerful treatment option. Metformin’s safety profile and potential beneficial effects on inflammation and metabolic health make it a candidate for further study in these areas. If you're interested in exploring metformin as a treatment option, consult with your healthcare provider or visit RTHM Direct to learn how it can treat your specific health concerns and get you back on the path to better health.
Follow the Science
The text discusses the potential benefits of metformin in treating COVID-19 based on preclinical studies and three randomized controlled trials. The preclinical data suggest that metformin may inhibit SARS-CoV-2 replication, reduce viral entry into cells, improve cell viability after infection, and decrease the inflammatory response. The three clinical trials had mixed results, with one trial showing that metformin reduced the need for oxygen supplementation, viral load, and time to undetectable virus in those seeking outpatient COVID-19 treatment. Another larger trial found that metformin reduced the risk of emergency department visits, hospitalizations, or death by 42% through 14 days and 58% through 28 days. However, the trials had limitations like small sample sizes, biases, and differences in patient populations and metformin dosing.
Metformin's safety profile, low cost, and wide availability make it a promising candidate for further study as a COVID-19 treatment, especially if started early in the course of infection.
Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, Belani HK, Anderson BJ, Huling JD, Tignanelli CJ, Thompson JL, Pullen M, Wirtz EL, Siegel LK, Proper JL, Odde DJ, Klatt NR, Sherwood NE, Lindberg SM, Karger AB, Beckman KB, Erickson SM, Fenno SL, Hartman KM, Rose MR, Mehta T, Patel B, Griffiths G, Bhat NS, Murray TA, Boulware DR; COVID-OUT Study Team. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023 Oct;23(10):1119-1129. doi: 10.1016/S1473-3099(23)00299-2. Epub 2023 Jun 8. Erratum in: Lancet Infect Dis. 2023 Sep 1;: PMID: 37302406.
Spencer M. Erickson, Sarah L. Fenno, Nir Barzilai, George Kuchel, Jenna M. Bartley, Jamie Nicole Justice, John B. Buse, Carolyn T. Bramante; Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2. Diabetes Care 1 July 2023; 46 (7): 1432–1442. https://doi.org/10.2337/dc22-2539
Parthasarathy, H., Tandel, D., Siddiqui, A. H., & Harshan, K. H. (2023). Metformin suppresses SARS-CoV-2 in cell culture. Virus Research, 323. https://doi.org/10.1016/j.virusres.2022.199010
Carolyn T Bramante, Kenneth B Beckman, Tanvi Mehta, Amy B Karger, David J Odde, Christopher J Tignanelli, John B Buse, Darrell M Johnson, Ray H B Watson, Jerry J Daniel, David M Liebovitz, Jacinda M Nicklas, Ken Cohen, Michael A Puskarich, Hrishikesh K Belani, Lianne K Siegel, Nichole R Klatt, Blake Anderson, Katrina M Hartman, Via Rao, Aubrey A Hagen, Barkha Patel, Sarah L Fenno, Nandini Avula, Neha V Reddy, Spencer M Erickson, Regina D Fricton, Samuel Lee, Gwendolyn Griffiths, Matthew F Pullen, Jennifer L Thompson, Nancy E Sherwood, Thomas A Murray, Michael R Rose, David R Boulware, Jared D Huling, for the COVID-OUT Study Team, Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019, Clinical Infectious Diseases, 2024;, ciae159, https://doi.org/10.1093/cid/ciae159
